Previous 10 | Next 10 |
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2023. “So far this year, we have ac...
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in the 2023 Bank of America Securities Healthcare Conference. ...
2023-03-29 07:37:25 ET Summary Last year, ALPN ditched its lead program after a second patient death in a CD28 molecule, a previously notorious pathway. ALPN has started all over again, with backing from a few big pharma. They do have a decent cash runway. Alpine Imm...
2023-03-23 19:41:05 ET Alpine Immune Sciences, Inc. (ALPN) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants Temre Johnson - SD, IR Mitchell Gold - Executive Chairman, CEO Stanford Peng - President, Head of R&D Paul Rickey - ...
2023-03-23 16:08:28 ET Alpine Immune Sciences press release ( NASDAQ: ALPN ): Q4 GAAP EPS of -$0.41 misses by $0.14 . Revenue of $2.78M (-38.6% Y/Y) misses by $8.18M . For further details see: Alpine Immune Sciences GAAP EPS of -$0.41 misses by $0.14, rev...
RUBY-3, a basket study of povetacicept in autoimmune glomerulonephritis, has initiated patient enrollment; RUBY-4, a basket study of povetacicept in autoimmune cytopenias, targets initiation in Q2 2023 Initial data from both basket studies are anticipated by the end of 2023 ...
2023-03-22 17:35:34 ET Alpine Immune Sciences ( NASDAQ: ALPN ) is scheduled to announce Q4 earnings results on Thursday, March 23rd, after market close. The consensus EPS Estimate is -$0.26 (+50.0% Y/Y) and the consensus Revenue Estimate is $10.96M (+141.9% Y/Y). For...
2023-03-22 17:35:12 ET Major earnings expected after the bell on Thursday include: Ideanomics ( IDEX ) Planet 13 Holdings ( OTCQX:PLNHF ) Spruce Power Holding Corporation ( SPRU ) Heron Therapeutics ( HRTX ) ADMA Biologics ( ADMA ) For further...
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, will present posters at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) Annual Meeting and ...
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, will present an ePoster with an oral presentation at the American Academy of Dermatology (AAD) Annual Meeting, highli...
News, Short Squeeze, Breakout and More Instantly...
Alpine Immune Sciences Inc. Company Name:
ALPN Stock Symbol:
NASDAQ Market:
Alpine Immune Sciences Inc. Website:
FREMONT, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the election of Mitchell H. Gold, M.D., and Angie You, Ph.D., as independent members of its Board of Directors. Drs. Gold and You are seasoned biotech executives and experienced board members who bring decades...
2024-05-19 02:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2024. On April 10, 2024, Vertex Pharmaceutic...